EUCTR2014-000172-26-ES进行中（未招募）1 期
A multicentre, open label, phase IIb clinical trial to evaluate safety, tolerability and efficacy of the depigmented modified allergen extract of two mites mixes at 200 DPP/ml (DP/MG/14-1 Dermatophagoides pteronyssinus / Lepidoglyphus destructor and DP/MG/14-2 Dermatophagoides pteronyssinus /Blomia tropicalis) in subjects with allergic rhinitis or rhinoconjunctivitis, with controlled allergic asthma.
aboratorios LETI S.L.0 个研究点目标入组 67 人开始时间: 2014年5月8日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 67
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Subject has provided appropriately signed and dated written informed consent.
- •2.Men and women aged ? 18 years and ? 70 years of age at Visit 1.
- •3.Has an FEV1 value ? 80% of predicted normal value at Visit 1.
- •4.Individuals suffering from perennial allergic rhinitis or rhinoconjunctivitis moderate-severe (see Annex 8 in order to verify the disease burden) for at least the preceding year, with controlled asthma, caused by double sensitization against Dermatophagoides pteronyssinus (DPT) and Lepidoglyphus destructor or Dermatophagoides pteronyssinus and Blomia tropicalis.
- •?The IgE-mediated sensitization must be verified by the following:
- •o Suggestive medical history, and
- •o Specific IgE to D. pteronyssinus and Lepidoglyphus destructor or D. pteronyssinus and Blomia tropicalis ? 0,7 KU/l (classe II). The IgE results are valid if performed within one year prior to V1, and
- •o Positive skin prick test (SPT) to D. pteronyssinus and Lepidoglyphus destructor or Blomia tropicalis.
- •A SPT will be considered positive when it produces a wheal whose diameter is at least 3 mm. The negative control must not develop a wheal or it must be smaller than the DPT one in 3 mm.
- •- Asthmatic subjects can be included in the trial only if allergic asthma is controlled according to the Global Initiative for Asthma (GINA 2010)
- •- Asthmatic subjects must be stable within 3 months prior to Visit 1 and on a stable inhaled steroid dose within 6 weeks prior to Visit 1 and throughout the study.
- •5.Patients sensitized to co-allergens such as tree pollen, grasses or weeds, fungi or animal epithelials cannot participate in the study if they are symptomatic. Patients sensitized to animal dander can participate only if they are not exposed.
- •6.If a female is of non-childbearing potential, the subject must be postmenopausal for at least 1 year or surgically sterile (e.g., bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).
- •7.If a female is of childbearing potential, the subject must be non-lactating and non-pregnant (with a negative pregnancy test result at Visit 1) and must correctly use an effective method of contraception during the study. An effective method of contraception is defined as one that results in a failure rate of less than 1% per year. The following are allowed methods of contraception when used continuously and properly: hormonal contraceptives administered by implant, injection, or orally; complete abstinence; partner?s vasectomy if the female has not more than one partner. Barrier methods (e.g., preservatives) are only considered effective if used together with one of the above.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 64
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 3
排除标准
- •1.Any contraindication for treatment with allergen specific immunotherapy.
- •2.Subjects with a previous history of anaphylaxis.
- •3.Patients with hospital admission due to asthma exacerbations within 1 year prior to V1.
- •4.Has uncontrolled asthma, according to Global Initiative for Asthma Guidelines (GINA 2010).
- •5.Acute or chronic infectious conjunctivitis.
- •6.Has acute or chronic inflammatory or infectious airways disease.
- •7.Has chronic structural diseases of the affected organ (e.g. eye, nose, lung).
- •8.History or presence of confirmed or potential diseases of the immune system including autoimmune diseases and immune deficiencies of actual clinical relevance.
- •9.Has any disease that prohibits the use of adrenaline (e.g., hyperthyroidism).
- •10.Has a severe uncontrolled disease that could increase the risk to the subjects while participating in the study, including but not limited to, the following: cardiovascular insufficiency, any severe or unstable lung diseases, endocrine diseases, clinically significant renal or hepatic diseases or haematological disorders.
- •11.Subjects with chronic urticaria.
- •12.Subjects with moderate-severe atopic dermatitis (subjects with a SCORAD value >30 can not participate in the study).
- •13.Has had active malignant disease during the previous 5 years.
- •14.Has a significant abnormal laboratory parameter or alteration in vital signs that could increase the risk to the study patient.
- •15.Has used immunotherapy with allergenic extracts of storage or house dust mites within the last 5 years or is receiving allergen specific immunotherapy with other allergens during the study period.
- •16.Has used systemic and/or topical treatment with beta-blocker drugs within 1 week prior to Visit 2 (first IMP administration).
- •17.Used psychotropic, tricyclic, tetracyclic and MAOI antidepressants within 1 month prior to Visit 1. It will not be allowed to perform a washout period of psychotropic or antidepressants to enter the study because of the risks of interrupting the treatment.
- •18.Used systemic corticosteroids within 3 months prior to Visit 1.
- •19.Treatment with substances interfering with the immune system 2 weeks before Visit 2 (first IMP administration).
- •20.Immunization with prophylactic (bacterial or viral) vaccines within 7 days prior to Visit 1 and within 7 days prior to visit 2 (first IMP administration). Prophylactic vaccines are allowed during the administration of IMP period provided they are administered at least one week after immunotherapy and the next immunotherapy dose is administered at least 14 days later.
- •21.Exposure to any investigational drug within one month or 6 half lives of the drug (whichever is longer).
- •22.Has abused alcohol, drugs or medications within the past year prior to Visit 1.
- •23.Lack of cooperation or compliance.
- •24.Donation of germ cells, blood, organs and/or bone marrow for the duration of the study.
研究者
相似试验
进行中（未招募）
1 期
A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by ofatumumab and ibrutinib followed by ibrutinib and ofatumumab maintenance in CLL patients (CLL2-BIO-trial of the GCLLSG)Fit and unfit patients with previously untreated or relapsed/refractory CLL requiring treatmentMedDRA version: 20.0Level: PTClassification code 10008958Term: Chronic lymphocytic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-000590-39-DEniversity of Cologne62
进行中（未招募）
1 期
A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 and ibrutinib (BIG) followed by ibrutinib and GA101 maintenance in CLL patients (CLL2-BIG protocol)Fit and unfit patients with previously untreated or relapsed/refractory CLL requiring treatmentMedDRA version: 19.1 Level: PT Classification code 10008958 Term: Chronic lymphocytic leukaemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-000569-35-DEniversity of Cologne62
进行中（未招募）
1 期
Evaluation of a treatment with bendamustine, followed by obinutuzumab, acalabrutinib and venetoclax in patients with relapsed chronic lymphocytic leukemiaPatients with relapsed/refractory CLL requiring treatmentMedDRA version: 21.1Level: PTClassification code 10008958Term: Chronic lymphocytic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003133-28-DEniversität zu Köln46
已完成
2 期
A prospective, open-label, multicenter phase-II trial to evatuate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 and ibrutinib followed by ibrutinib and GA101 maintenance in CLL patientsC91.1Chronic lymphocytic leukaemia of B-cell typeDRKS00007710niversität zu Köln66
进行中（未招募）
1 期
Evaluation of a treatment with bendamustine, followed by obinutuzumab,zanubrutinib and venetoclax in patients with relapsed chronic lymphocyticleukemiaPatients with relapsed/refractory CLL requiring treatmentMedDRA version: 21.1Level: PTClassification code 10008958Term: Chronic lymphocytic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003270-27-DEniversität zu Köln B.1.240